Vanguard Personalized Indexing Management
ESPR

Vanguard Personalized Indexing Management’s Esperion Therapeutics ESPR Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8K Buy
13,236
+1,055
+9% +$2.95K ﹤0.01% 2156
2026
Q1 		$33.4K Buy
12,181
+769
+7% +$2.43K ﹤0.01% 2091
2025
Q4 		$42.2K Buy
11,412
+323
+3% +$1.04K ﹤0.01% 1900
2025
Q3 		$29.4K Buy
+11,089
New +$21.4K ﹤0.01% 1949

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Vanguard Personalized Indexing Management's ESPR Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Esperion Therapeutics (ESPR) stake by 8.7% in Q2 2026, buying an estimated $2.95K and bringing the position to 13,236 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

Vanguard Personalized Indexing Management first reported a position in ESPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $42.2K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Vanguard Personalized Indexing Management held 13,236 shares of Esperion Therapeutics worth $41.8K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 1,055 Esperion Therapeutics shares in Q2 2026, an estimated $2.95K.
  • Esperion Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2156 holding.
  • Vanguard Personalized Indexing Management first reported a position in Esperion Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Vanguard Personalized Indexing Management's Esperion Therapeutics position peaked at $42.2K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.